| Name | Title | Contact Details |
|---|---|---|
Dilshan Kathriarachchi |
Chief Technology Officer | Profile |
Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.
Codice is an information technology and business process outsourcing company that delivers solutions to government agencies and corporations, with a focus on healthcare administrative and oversight processes.
CDK Global is the largest provider of automotive dealership solutions for auto dealers, including retailing, CRM, financing, parts and service, IT infrastructure, and dealership operations. Find out how CDK can help you grow your business.
The HotDrop is an easy-to-scale, simple-to-install metering solution that provides minute-by-minute data to improve energy consumption data without the complexities and high price tag of traditional submeters.
Kaleris is the leading provider of transportation and asset management software for accelerated supply chain execution.